Exhibit 4.4


 


DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934


 


The following description of the securities
of Oramed Pharmaceuticals Inc. (the “Company”) is a summary only. This summary is not complete and is subject to and
qualified by the provisions of the Company’s Certificate of Incorporation, as amended (the “Charter”), and Amended
and Restated By-laws, as amended (the “By-laws”), which are filed as exhibits to the Company’s Annual Report
on Form 10-K for the fiscal year ended August 31, 2020 and are incorporated by reference herein.


 


Common Stock


 


Pursuant to the Company’s Charter,
the Company is authorized to issue up to sixty million (60,000,000) shares of common stock, par value $0.012 per share (the “Common
Stock”).


 


The Common Stock is traded on The Nasdaq
Capital Market and the Tel Aviv Stock Exchange, in each case under the symbol “ORMP”.


 


The holders of shares of Common Stock vote
together as one class on all matters as to which holders of Common Stock are entitled to vote. Except as otherwise required by
applicable law, all voting rights are vested in and exercised by the holders of Common Stock with each share of Common Stock being
entitled to one vote, including in all elections of directors. The Company does not have a classified board of directors (the “Board”).


 


The holders of Common Stock are entitled
to receive ratably such dividends, if any, as may be declared from time to time by the Board out of legally available funds therefore.
The Company has not declared any dividends on its Common Stock and does not anticipate paying any dividends on its Common Stock
in the foreseeable future.


 


In the event of the Company’s liquidation,
dissolution or winding up, holders of the Common Stock are entitled to share ratably in all assets remaining after payment of liabilities.
The Common Stock has no cumulative voting rights and no preemptive or other rights to subscribe for shares of the Company.


 


There are no redemption or sinking fund
provisions applicable to the Common Stock. All shares of Common Stock currently outstanding are fully paid and non-assessable.


 


The Company is permitted to issue, and
has from time to time, issued warrants and options to purchase shares of the Common Stock, as well as restricted stock units.


 






     


     


    

 


Anti-Takeover Effects of the Company’s
Charter and By-Laws


 


In addition to provisions under Delaware
law, the Company’s Charter and By-Laws contain provisions that could have the effect of discouraging potential acquisition
proposals or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider
favorable. In particular, the Charter and/or By-Laws, as applicable, among other things:


 


		●	provide the Board with the exclusive authority to call special meetings of the stockholders;



 


		●	provide the Board with the ability to alter the By-Laws without stockholder approval;



 


		●	provide the Board with the exclusive authority to fix the number of directors constituting the
whole Board; and



 


		●	provide that vacancies on the Board may be filled by a majority of directors in office, although
less than a quorum.



 


Such provisions may have the effect of
discouraging a third-party from acquiring the Company, even if doing so would be beneficial to the Company’s stockholders.
These provisions are intended to enhance the likelihood of continuity and stability in the composition of the Board and in its
policies, and to discourage some types of transactions that may involve an actual or threatened change in control of the Company.
These provisions are designed to reduce the Company’s vulnerability to an unsolicited acquisition proposal and to discourage
some tactics that may be used in proxy fights. The Company believes that the benefits of increased protection of its potential
ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure the Company outweigh
the disadvantages of discouraging such proposals because, among other things, negotiation of such proposals could result in an
improvement of their terms. However, these provisions could have the effect of discouraging others from making tender offers for
shares of the Company’s Common Stock and, as a consequence, they also may inhibit fluctuations in the market price of the
shares of the Company’s Common Stock that could result from actual or rumored takeover attempts. These provisions also may
have the effect of preventing changes in the Company’s management.